Jamie P. Dwyer MDProfessor of Medicine, Director of the Nephrology Clinical Trials Center, Vanderbilt University Medical Center, Nashville, Tennessee
Jamie P Dwyer, MD, is currently Professor of Medicine in the Division of Nephrology and Hypertension, Vanderbilt University Medical Center (VUMC), in Nashville, TN. He is the Director of the Nephrology Clinical Trials Center at VUMC, and determines the overall clinical trials research agenda for the Division of Nephrology. He is the current President and Principal Investigator of the Collaborative Study Group (CSG), an international academic research organization dedicated to the exceptionally rigorous design, conduct, analysis, and reporting of large, multicenter clinical trials. He has served on multiple steering committees and executive committees for large trials, particularly in renal progression and cardiovascular outcomes, and served as a Consultant to the US Food and Drug Administration’s (FDA) CardioRenal Advisory Committee 2015-2019. Dr. Dwyer holds an Sc.B degree in mathematics and Latin from Brown University, and an M.D. with Distinction from Brown University Medical School. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at VUMC. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of VUMC in 2008.
Dr. Dwyer serves as a consultant to AstraZeneca for the Dapagliflozin program in Cardiovascular outcomes (DECLARE-TIMI-58 trial) and in renal failure progression (DAPA-CKD), and consultant to Sanofi for the sotagliflozin program in cardiovascular outcomes (serving on the Steering Committee for the SCORED trial).
Recent Contributions to PracticeUpdate:
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With HFrEF
- Diuretic and Cardio-Renal Effects of Empagliflozin in Patients With Heart Failure
- Canagliflozin Reduces Cardiovascular Events in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Prognostic Value of Albuminuria and Influence of Spironolactone in HFpEF